Andressa Wigner Brochier

Andressa Wigner Brochier

Auto-generated profile, based on publicly available information

Andressa Wigner Brochier

Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2017 in Frontiers in Neurology
Verified
Journal Article
Open access
Adriano Martimbianco de AssisAdriano Martimbianco de Assis
Adriano Martimbianco de Assis
JSJonas Alex Morales Saute
Jonas Alex Morales Saute
ALAline Longoni
Aline Longoni
CHClarissa Branco Haas
Clarissa Branco Haas
VTVitor Rocco Torrez
Vitor Rocco Torrez
LPLuis Valmor Portela
Luis Valmor Portela
Objectives: Spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD) is a polyglutamine disorder with no current disease-modifying treatment. Conformational changes of mutant ataxin-3 trigger different pathogenic cascades, including reactive oxygen species (ROS) generation; however, the clinical relevance of oxidative stress elements as peripheral biomarkers of SCA3/MJD remains unknown. We aimed to evaluate ROS production and antioxidant defense capacity in symptomatic and presymptomatic SCA3/MJD individuals and correlate these markers with clinical and molecular data with the goal of assessing their properties as disease biomarkers. Methods: Molecularly confirmed SCA3/MJD carriers and controls were included in an exploratory case-control study. Serum ROS, measured by 2′, 7′-dichlorofluorescein (DCFH-DA) as well as superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) antioxidant enzyme activities, levels were assessed. Results: Fifty-eight early/moderate stage symptomatic SCA3/MJD, 12 presymptomatic SCA3/MJD, and 47 control individuals were assessed. The DCFH-DA levels in the symptomatic group were 152.82 nmol/mg of protein (95% confidence interval (CI), 82.57 to 223.08, p<0.001) higher than in the control and 243.80 nmol/mg of protein (95% CI, 130.64 to 356.96, p<0.001) higher than in the presymptomatic group. The SOD activity in the symptomatic group was 3 U/mg of protein (95% CI, 0.015 to 6.00, p=0.048) lower than in the presymptomatic group. The GSH-Px activity in the symptomatic group was 13.96 U/mg of protein (95% CI, 5.90 to 22.03, p<0.001) lower than in the control group and 20.52 U/mg of protein (95% CI, 6.79 to 34.24, p<0.001) lower than in the presymptomatic group and was inversely correlated with the neurological examination score for spinocerebellar ataxias (R=-0.309, p=0.049). Conclusions: Early/moderate stage SCA3/MJD patients presented a decreased antioxidant capacity and increased ROS generation. GSH-Px activity was the most promising oxidative stress disease biomarker in SCA3/MJD. Further longitudinal studies are necessary to identify both the roles of redox parameters in SCA3/MJD pathophysiology and as surrogate outcomes for clinical trials.

26 October 2015 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
CHClarissa B. Haas
Clarissa B. Haas
EKEduardo Kalinine
Eduardo Kalinine
EZEduardo Zimmer
Eduardo Zimmer
GHGisele Hansel
Gisele Hansel
ABAndressa W. Brochier
Andressa W. Brochier
AMAlexandre P. Muller
Alexandre P. Muller

22 September 2015 in The Cerebellum
Verified
Journal Article
Closed access
PDF file
GCGerson da Silva Carvalho
Gerson da Silva Carvalho
JSJonas Alex Morales Saute
Jonas Alex Morales Saute
CHClarissa Branco Haas
Clarissa Branco Haas
VTVitor Rocco Torrez
Vitor Rocco Torrez
ABAndressa Wigner Brochier
Andressa Wigner Brochier
LJLaura Bannach Jardim
Laura Bannach Jardim

1 September 2013 in Experimental Neurology
Verified
Journal Article
Closed access
AMAlexandre Pastoris Muller
Alexandre Pastoris Muller
CHClarissa Branco Haas
Clarissa Branco Haas
JCJuliana Camacho-Pereira
Juliana Camacho-Pereira
ABAndressa Wigner Brochier
Andressa Wigner Brochier
JGJussânia Gnoatto
Jussânia Gnoatto
LPLuis Valmor Portela
Luis Valmor Portela

10 December 2014 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
LPLuis Valmor Portela
Luis Valmor Portela
JGJussania Gnoatto
Jussania Gnoatto
ABAndressa Wigner Brochier
Andressa Wigner Brochier
CHClarissa Branco Haas
Clarissa Branco Haas
Adriano Martimbianco de AssisAdriano Martimbianco de Assis
Adriano Martimbianco de Assis
AMAlexandre Pastoris Muller
Alexandre Pastoris Muller

22 September 2016 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
LPLuis V. Portela
Luis V. Portela
ABAndressa W. Brochier
Andressa W. Brochier
CHClarissa B. Haas
Clarissa B. Haas
ACAfonso Kopczynski de Carvalho
Afonso Kopczynski de Carvalho
JGJussania A. Gnoato
Jussania A. Gnoato
AMAlexandre P. Muller
Alexandre P. Muller